At a glance
ClinicalIndex Comparison RecordN/ACompleted· 291 enrolled
Drug / intervention
CAL/BDP PAD Creamdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An International, Prospective, Observational Cohort Study to Assess Patient Treatment Satisfaction, Patient-reported Outcomes, Effectiveness, and Safety of a Fixed-dose Combination of Calcipotriene/Betamethasone Dipropionate PAD Cream in the Treatment of Mild-to-moderate Plaque Psoriasis of the Scalp in Adults (PRO-SCALP)
In Brief
An observational study evaluating CAL/BDP PAD Cream for Plaque Psoriasis. Completed, enrolled 291 participants across 37 sites in 3 countries.
Detailed Summary
The main aim of this study is to assess treatment satisfaction, quality of life, treatment preference, adherence and convenience, psychosocial effects of scalp psoriasis, sleep quality, and effectiveness, and safety of Calcipotriene/Betamethasone Dipropionate (CAL/BDP) PAD cream in a real-world setting.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsPlaque Psoriasis
CountriesGermany, Spain, United Kingdom
Collaborators--
Timeline
N/ACompletedFinished
202420252026
First PostedApr 2023
Enrollment StartJun 2023
Primary CompletionOct 2024
TodayJul 2026
First PostedApr 13, 2023
Enrollment StartJun 13, 2023
Primary CompletionOct 1, 2024
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 3.2 years ago
Interventions
CAL/BDP PAD Creamdrug
As provided in real-world clinical practice.